Engineered T cells for cancer treatment

Cytotherapy

Volumn 16, Issue 6, 2014, Pages 713-733

  Anurathapan, Usanarat ^a   Leen, Ann M ^a   Brenner, Malcolm K ^a   Vera, Juan F ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Cancer treatment; CAR T cells; Genetic modification of T cells; Immunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN GP 100; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MELAN A; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; HYBRID PROTEIN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIGEN SPECIFICITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL ENGINEERING; CELL SURVIVAL; CELL THERAPY; CHIMERA; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CYTOKINE STORM; DNA MODIFICATION; DRUG SAFETY; ESOPHAGUS CANCER; EX VIVO GENE TRANSFER; GENE TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNOSTIMULATION; IN VIVO STUDY; LUNG TOXICITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFER; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNOVIAL SARCOMA; T LYMPHOCYTE; TARGET ORGAN; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; BIOSYNTHESIS; CYTOLOGY; CYTOTOXICITY; GENETICS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANTIGENS, NEOPLASM; CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84899932784     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.10.002     Document Type: Article

References (233)

1. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
2. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. JImmunother 2001, 24:363-373.
3. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
4. Rosenberg S.A., Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2):14639-14645.
5. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. JClin Oncol 2005, 23:2346-2357.
6. Rooney C.M., Smith C.A., Ng C., Loftin S.K., Li C., Krance R.A., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995, 345:9-13.
7. Heslop H.E., Ng C.Y.C., Li C., Smith C.A., Loftin S.K., Krance R.A., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
8. Heslop H.E., Slobod K.S., Pule M.A., Hale G.A., Rousseau A., Smith C.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
9. Bollard C.M., Gottschalk S., Leen A.M., Weiss H., Straathof K.C., Carrum G., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110:2838-2845.
10. Bollard C.M., Straathof K.C., Huls M.H., Leen A., Lacuesta K., Davis A., et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. JImmunother 2004, 27:317-327.
11. Bollard C.M., Aguilar L., Straathof K.C., Gahn B., Huls M.H., Rousseau A., et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. JExp Med 2004, 200:1623-1633.
12. Straathof K.C., Leen A.M., Buza E.L., Taylor G., Huls M.H., Heslop H.E., et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. JImmunol 2005, 175:4137-4147.
13. Straathof K.C., Bollard C.M., Popat U., Huls M.H., Lopez T., Morriss M.C., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005, 105:1898-1904.
14. Louis C.U., Straathof K., Bollard C.M., Gerken C., Huls M.H., Gresik M.V., et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009, 113:2442-2450.
15. Leen A.M., Rooney C.M., Foster A.E. Improving T cell therapy for cancer. Annu Rev Immunol 2007, 25:243-265.
16. Scholler J., Brady T.L., Binder-Scholl G., Hwang W., Plesa G., Hege K.M., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012, 1:132ra53.
17. Bear A.S., Morgan R.A., Cornetta K., June C.H., Binder-Scholl G., Dudley M.E., et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?. Mol Ther 2012, 20:246-249.
18. Singh H., Manuri P.R., Olivares S., Dara N., Dawson M.J., Huls H., et al. Redirecting specificity of T-cell populations forCD19 using the Sleeping Beauty system. Cancer Res 2008, 68:2961-2971.
19. Hackett P.B., Aronovich E.L., Hunter D., Urness M., Bell J.B., Kass S.J., et al. Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 2011, 11:341-349.
20. Izsvak Z., Hackett P.B., Cooper L.J., Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. BioEssays 2010, 32:756-767.
21. Nakazawa Y., Huye L.E., Dotti G., Foster A.E., Vera J.F., Manuri P.R., et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. JImmunother 2009, 32:826-836.
22. Li L.P., Lampert J.C., Chen X., Leitao C., Popovic J., Muller W., et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 2010, 16:1029-1034.
23. Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W., et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. JClin Invest 2010, 120:3869-3877.
24. Stauss H.J., Cesco-Gaspere M., Thomas S., Hart D.P., Xue S.A., Holler A., et al. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther 2007, 15:1744-1750.
25. Davis J.L., Theoret M.R., Zheng Z., Lamers C.H., Rosenberg S.A., Morgan R.A. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res 2010, 16:5852-5861.
26. Cohen C.J., Li Y.F., El-Gamil M., Robbins P.F., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007, 67:3898-3903.
27. Linnemann C., Schumacher T.N., Bendle G.M. T-cell receptor gene therapy: critical parameters for clinical success. JInvest Dermatol 2011, 131:1806-1816.
28. Jorritsma A., Schotte R., Coccoris M., De Witte M.A., Schumacher T.N. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther 2011, 11:276-287.
29. Provasi E., Genovese P., Lombardo A., Magnani Z., Liu P.Q., Reik A., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012, 18:807-815.
30. Torikai H., Reik A., Liu P.Q., Zhou Y., Zhang L., Maiti S., et al. Afoundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012, 119:5697-5705.
31. Hiasa A., Nishikawa H., Hirayama M., Kitano S., Okamoto S., Chono H., et al. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. Gene Ther 2009, 16:620-628.
32. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
33. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., et al. Tcells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011, 19:620-626.
34. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. JClin Oncol 2011, 29:917-924.
35. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. JImmunother 2013, 36:133-151.
36. He Z.F., Lv W., Qiao J., Chen Z.M., Pang L.W., Chen X.J. Thymic expression of the main immunogenic region of titin in thymomatous myasthenia gravis. JInt Med Res 2010, 38:1324-1332.
37. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., et al. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 2013, 122:863-871.
38. Cameron B.J., Gerry A.B., Dukes J., Harper J.V., Kannan V., Bianchi F.C., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013, 5:197ra103.
39. Ramos C.A., Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011, 11:855-873.
40. Savoldo B., Ramos C.A., Liu E., Mims M.P., Keating M.J., Carrum G., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified Tcells in lymphoma patients. JClin Invest 2011, 121:1822-1826.
41. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733.
42. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
43. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. NEngl J Med 2013, 368:1509-1518.
44. Heslop H.E. Safer CARS. Mol Ther 2010, 18:661-662.
45. Buning H., Uckert W., Cichutek K., Hawkins R.E., Abken H. Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther 2010, 21:1039-1042.
46. Peinert S., Kershaw M.H., Prince H.M. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future. Immunotherapy 2009, 1:905-912.
47. Lamers C.H., Willemsen R., van E.P., van Steenbergen-Langeveld S., Broertjes M., Oosterwijk-Wakka J., et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117:72-82.
48. Lamers C.H., Langeveld S.C., Groot-van Ruijven C.M., Debets R., Sleijfer S., Gratama J.W. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 2007, 56:1875-1883.
49. Lamers C.H., Sleijfer S., Vulto A.G., Kruit W.H., Kliffen M., Debets R., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. JClin Oncol 2006, 24:e20-e22.
50. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., et al. Aphase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12:6106-6115.
51. Jensen M.C., Popplewell L., Cooper L.J., DiGiusto D., Kalos M., Ostberg J.R., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010, 16:1245-1256.
52. Brentjens R.J., Riviere I., Hollyman D., Taylor C., Nikhamin Y., Stefanski J., et al. Unexpected toxicity of cyclophosphamide followed by adoptively transferred CD19-targeted T cells in a patient with bulky CLL. Mol Ther 2009, 17(Suppl. 1):S157.
53. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
54. Parente-Pereira A.C., Burnet J., Ellison D., Foster J., Davies D.M., van der Stegen S., et al. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. JClin Immunol 2011, 31:710-718.
55. Wilkie S., van Schalkwyk M.C., Hobbs S., Davies D.M., van der Stegen S.J., Pereira A.C., et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. JClin Immunol 2012, 32:1059-1070.
56. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signallung promotes selective tumor eradication by engineered T cells. Nat Biotech 2013, 31:71-75.
57. Lo A.S.Y., Taylor J.R., Farzanch F., Kemeny D.M., Dibb N.J., Maher J. Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Mol Immunol 2007, 45:1276-1287.
58. Wilkie S., Burbridge S.E., Chiapero-Stanke L., Pereira A.C., Cleary S., van der Stegen S.J., et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. JBiol Chem 2010, 285:25538-25544.
59. Sanchez C., Chan R., Bajgain P., Rambally S., Palapattu G., Mims M., et al. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis 2013, 16:123-131.
60. Di S.A., De A.B., Rooney C.M., Zhang L., Mahendravada A., Foster A.E., et al. Tlymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
61. Moon E.K., Carpenito C., Sun J., Wang L.C., Kapoor V., Predina J., et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011, 17:4719-4730.
62. Craddock J.A., Lu A., Bear A., Pule M., Brenner M.K., Rooney C.M., et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. JImmunother 2010, 33:780-788.
63. Ahmadzadeh M., Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107:2409-2414.
64. Quintarelli C., Vera J.F., Savoldo B., Giordano Attianese G.M., Pule M., Foster A.E., et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007, 110:2793-2802.
65. Hoyos V., Savoldo B., Quintarelli C., Mahendravada A., Zhang M., Vera J., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.
66. Vera J.F., Hoyos V., Savoldo B., Quintarelli C., Giordano Attianese G.M., Leen A.M., et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009, 17:880-888.
67. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. JImmunother 2006, 29:313-319.
68. Sportes C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. JExp Med 2008, 205:1701-1714.
69. Sportes C., Babb R.R., Krumlauf M.C., Hakim F.T., Steinberg S.M., Chow C.K., et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010, 16:727-735.
70. Perales M.A., Goldberg J.D., Yuan J., Koehne G., Lechner L., Papadopoulos E.B., et al. Recombinant human interleukin-7 (CYT107) promotes T cell recovery following allogeneic stem cell transplantation. Blood 2012, 120:4882-4891.
71. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., et al. Ahuman memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
72. Geginat J., Lanzavecchia A., Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003, 101:4260-4266.
73. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. JExp Med 2005, 201:139-148.
74. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. JClin Invest 2008, 118:294-305.
75. Wang A., Chandran S., Shah S.A., Chiu Y., Paria B.C., Aghamolla T., et al. The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 2012, 4:149ra120.
76. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
77. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
78. Terakura S., Yamamoto T.N., Gardner R.A., Turtle C.J., Jensen M.C., Riddell S.R. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012, 119:72-82.
79. Stephan M.T., Ponomarev V., Brentjens R.J., Chang A.H., Dobrenkov K.V., Heller G., et al. Tcell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007, 13:1440-1449.
80. Dagarag M., Evazyan T., Rao N., Effros R.B. Genetic manipulation of telomerase in HIV-specific CD8+ T cells: enhanced antiviral functions accompany the increased proliferative potential and telomere length stabilization. JImmunol 2004, 173:6303-6311.
81. Hooijberg E., Ruizendaal J.J., Snijders P.J., Kueter E.W., Walboomers J.M., Spits H. Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. JImmunol 2000, 165:4239-4245.
82. Migliaccio M., Amacker M., Just T., Reichenbach P., Valmori D., Cerottini J.C., et al. Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization. JImmunol 2000, 165:4978-4984.
83. Charo J., Finkelstein S.E., Grewal N., Restifo N.P., Robbins P.F., Rosenberg S.A. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 2005, 65:2001-2008.
84. Eaton D., Gilham D.E., O'Neill A., Hawkins R.E. Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther 2002, 9:527-535.
85. Dotti G., Savoldo B., Pule M., Straathof K.C., Biagi E., Yvon E., et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005, 105:4677-4684.
86. Bollard C.M., Rossig C., Calonge M.J., Huls M.H., Wagner H.J., Massague J., et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002, 99:3179-3187.
87. Lacuesta K., Buza E., Hauser H., Granville L., Pule M., Corboy G., et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. JImmunother 2006, 29:250-260.
88. Foster A.E., Dotti G., Lu A., Khalil M., Brenner M.K., Heslop H.E., et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. JImmunother 2008, 31:500-505.
89. Introna M., Barbui A.M., Bambacioni F., Casati C., Gaipa G., Borleri G., et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 2000, 11:611-620.
90. Serafini M., Manganini M., Borleri G., Bonamino M., Imberti L., Biondi A., et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 2004, 15:63-76.
91. Bonini C., Ciceri F., Marktel S., Magnani Z., Cazzaniga S., Zappone E., et al. Abrogation of GvHD and early immune reconstitution after infusion of HSV-TK engineered donor lymphocytes after haplo-identical hematopoietic stem cell transplantation. Blood 2002, 100:115a.
92. Bonini C., Bondanza A., Perna S.K., Kaneko S., Traversari C., Ciceri F., et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007, 15:1248-1252.
93. Ciceri F., Bonini C., Marktel S., Zappone E., Servida P., Bernardi M., et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007, 109:4698-4707.
94. Ciceri F., Bonini C., Stanghellini M.T., Bondanza A., Traversari C., Salomoni M., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009, 10:489-500.
95. Traversari C., Marktel S., Magnani Z., Mangia P., Russo V., Ciceri F., et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007, 109:4708-4715.
96. Marin V., Cribioli E., Philip B., Tettamanti S., Pizzitola I., Biondi A., et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 2012, 23:376-386.
97. Straathof K.C., Pule M.A., Yotnda P., Dotti G., Vanin E.F., Brenner M.K., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105:4247-4254.
98. Ramos C.A., Asgari Z., Liu E., Yvon E., Heslop H.E., Rooney C.M., et al. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 2010, 28:1107-1115.
99. Di S.A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. NEngl J Med 2011, 365:1673-1683.
100. Tamada K., Geng D., Sakoda Y., Bansal N., Srivastava R., Li Z., et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res 2012, 18:6436-6445.
101. Urbanska K., Powell D.J. Development of a novel universal immune receptor for antigen targeting: to Infinity and beyond. Oncoimmunology 2012, 1:777-779.
102. Urbanska K., Lanitis E., Poussin M., Lynn R.C., Gavin B.P., Kelderman S., et al. Auniversal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 2012, 72:1844-1852.
103. Carswell K.S., Papoutsakis E.T. Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: shear, proliferation, and the IL-2 receptor. Biotechnol Bioeng 2000, 68:328-338.
104. Hami L.S., Green C., Leshinsky N., Markham E., Miller K., Craig S. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. Cytotherapy 2004, 6:554-562.
105. Klapper J.A., Thomasian A.A., Smith D.M., Gorgas G.C., Wunderlich J.R., Smith F.O., et al. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. JImmunol Methods 2009, 345:90-99.
106. Sadeghi A., Pauler L., Anneren C., Friberg A., Brandhorst D., Korsgren O., et al. Large-scale bioreactor expansion of tumor-infiltrating lymphocytes. JImmunol Methods 2011, 364:94-100.
107. Somerville R.P., Devillier L., Parkhurst M.R., Rosenberg S.A., Dudley M.E. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE bioreactor. JTransl Med 2012, 10:69.
108. Hollyman D., Stefanski J., Przybylowski M., Bartido S., Borquez-Ojeda O., Taylor C., et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. JImmunother 2009, 32:169-180.
109. Vera J.F., Brenner L.J., Gerdemann U., Ngo M.C., Sili U., Liu H., et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). JImmunother 2010, 33:305-315.
110. Lapteva N., Vera J.F. Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int 2011, 2011:434392.
111. Lapteva N., Durett A.G., Sun J., Rollins L.A., Huye L.L., Fang J., et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012, 14:1131-1143.
112. Jin J., Sabatino M., Somerville R., Wilson J.R., Dudley M.E., Stroncek D.F., et al. Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. JImmunother 2012, 35:283-292.
113. Cooper L.J., Topp M.S., Serrano L.M., Gonzalez S., Chang W.C., Naranjo A., et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003, 101:1637-1644.
114. Cooper L.J., Al-Kadhimi Z., DiGiusto D., Kalos M., Colcher D., Raubitschek A., et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004, 33:83-89.
115. Singh H., Serrano L.M., Pfeiffer T., Olivares S., McNamara G., Smith D.D., et al. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res 2007, 67:2872-2880.
116. Kowolik C.M., Topp M.S., Gonzalez S., Pfeiffer T., Olivares S., Gonzalez N., et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006, 66:10995-11004.
117. Loskog A., Giandomenico V., Rossig C., Pule M., Dotti G., Brenner M.K. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006, 20:1819-1828.
118. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009, 17:1453-1464.
119. Tammana S., Huang X., Wong M., Milone M.C., Ma L., Levine B.L., et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 2010, 21:75-86.
120. Brentjens R.J., Latouche J.B., Santos E., Marti F., Gong M.C., Lyddane C., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003, 9:279-286.
121. Brentjens R.J., Santos E., Nikhamin Y., Yeh R., Matsushita M., La P.K., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007, 13:5426-5435.
122. Kochenderfer J.N., Feldman S.A., Zhao Y., Xu H., Black M.A., Morgan R.A., et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. JImmunother 2009, 32:689-702.
123. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
124. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
125. Kebriaei P., Huls H., Jena B., Munsell M., Jackson R., Lee D.A., et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 2012, 23:444-450.
126. Brentjens R., Yeh R., Bernal Y., Riviere I., Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010, 18:666-668.
127. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
128. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra38.
129. James S.E., Orgun N.N., Tedder T.F., Shlomchik M.J., Jensen M.C., Lin Y., et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 2009, 114:5454-5463.
130. Jensen M., Tan G., Forman S., Wu A.M., Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998, 4:75-83.
131. Jensen M.C., Cooper L.J., Wu A.M., Forman S.J., Raubitschek A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003, 5:131-138.
132. Till B.G., Jensen M.C., Wang J., Chen E.Y., Wood B.L., Greisman H.A., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
133. Wang J., Press O.W., Lindgren C.G., Greenberg P., Riddell S., Qian X., et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 2004, 9:577-586.
134. Wang J., Jensen M., Lin Y., Sui X., Chen E., Lindgren C.G., et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007, 18:712-725.
135. Till B.G., Jensen M.C., Wang J., Qian X., Gopal A.K., Maloney D.G., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940-3950.
136. Haso W., Lee D.W., Shah N.N., Stetler-Stevenson M., Yuan C.M., Pastan I.H., et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013, 121:1165-1174.
137. Hombach A., Heuser C., Sircar R., Tillmann T., Diehl V., Pohl C., et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 1998, 58:1116-1119.
138. Savoldo B., Rooney C.M., Di S.A., Abken H., Hombach A., Foster A.E., et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007, 110:2620-2630.
139. Vera J., Savoldo B., Vigouroux S., Biagi E., Pule M., Rossig C., et al. Tlymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006, 108:3890-3897.
140. Shaffer D.R., Savoldo B., Yi Z., Chow K.K., Kakarla S., Spencer D.M., et al. Tcells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011, 117:4304-4314.
141. Tettamanti S., Marin V., Pizzitola I., Magnani C.F., Giordano Attianese G.M., Cribioli E., et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013, 161:389-401.
142. Barber A., Zhang T., Megli C.J., Wu J., Meehan K.R., Sentman C.L. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol 2008, 36:1318-1328.
143. Barber A., Meehan K.R., Sentman C.L. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther 2011, 18:509-516.
144. Spear P., Barber A., Rynda-Apple A., Sentman C.L. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. JImmunol 2012, 188:6389-6398.
145. Spear P., Barber A., Rynda-Apple A., Sentman C.L. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol 2013, 91:435-440.
146. Rossig C., Bollard C.M., Nuchtern J.G., Merchant D.A., Brenner M.K. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001, 94:228-236.
147. Rossig C., Bollard C.M., Nuchtern J.G., Rooney C.M., Brenner M.K. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002, 99:2009-2016.
148. Stancovski I., Schindler D.G., Waks T., Yarden Y., Sela M., Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. JImmunol 1993, 151:6577-6582.
149. Pinthus J.H., Waks T., Malina V., Kaufman-Francis K., Harmelin A., Aizenberg I., et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. JClin Invest 2004, 114:1774-1781.
150. Pisarev V., Yu B., Salup R., Sherman S., Altieri D.C., Gabrilovich D.I. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003, 9:6523-6533.
151. Ahmed N., Ratnayake M., Savoldo B., Perlaky L., Dotti G., Wels W.S., et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 2007, 67:5957-5964.
152. Zhao Y., Wang Q.J., Yang S., Kochenderfer J.N., Zheng Z., Zhong X., et al. Aherceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. JImmunol 2009, 183:5563-5574.
153. Yoon S.H., Lee J.M., Woo S.J., Park M.J., Park J.S., Kim H.S., et al. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR). JClin Immunol 2009, 29:806-814.
154. Yoon S.H., Lee J.M., Cho H.I., Kim E.K., Kim H.S., Park M.Y., et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther 2009, 16:489-497.
155. Ahmed N., Salsman V.S., Yvon E., Louis C.U., Perlaky L., Wels W.S., et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009, 17:1779-1787.
156. Birkholz K., Hombach A., Krug C., Reuter S., Kershaw M., Kampgen E., et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther 2009, 16:596-604.
157. Hwu P., Shafer G.E., Treisman J., Schindler D.G., Gross G., Cowherd R., et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. JExp Med 1993, 178:361-366.
158. Hwu P., Yang J.C., Cowherd R., Treisman J., Shafer G.E., Eshhar Z., et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995, 55:3369-3373.
159. Kershaw M.H., Westwood J.A., Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002, 20:1221-1227.
160. Parker L.L., Do M.T., Westwood J.A., Wunderlich J.R., Dudley M.E., Rosenberg S.A., et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000, 11:2377-2387.
161. Gonzalez S., Naranjo A., Serrano L.M., Chang W.C., Wright C.L., Jensen M.C. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. JGene Med 2004, 6:704-711.
162. Park J.R., Digiusto D.L., Slovak M., Wright C., Naranjo A., Wagner J., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
163. Weijtens M.E., Willemsen R.A., van Krimpen B.A., Bolhuis R.L. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 1998, 77:181-187.
164. Weijtens M.E., Willemsen R.A., Hart E.H., Bolhuis R.L. Aretroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther 1998, 5:1195-1203.
165. Lamers C.H., Sleijfer S., van S.S., van E.P., van K.B., Groot C., et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013, 21:904-912.
166. Gong M.C., Latouche J.B., Krause A., Heston W.D., Bander N.H., Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999, 1:123-127.
167. Maher J., Brentjens R.J., Gunset G., Riviere I., Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002, 20:70-75.
168. Brown C.E., Starr R., Aguilar B., Shami A.F., Martinez C., D'Apuzzo M., et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells. Clin Cancer Res 2012, 18:2199-2209.
169. Kahlon K.S., Brown C., Cooper L.J., Raubitschek A., Forman S.J., Jensen M.C. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166.
170. Stastny M.J., Brown C.E., Ruel C., Jensen M.C. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. JPediatr Hematol Oncol 2007, 29:669-677.
171. Kong S., Sengupta S., Tyler B., Bais A.J., Ma Q., Doucette S., et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012, 18:5949-5960.
172. Chow K.K., Naik S., Kakarla S., Brawley V.S., Shaffer D.R., Yi Z., et al. Tcells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 2012, 21:629-637.
173. Kakarla S., Chow K.K., Mata M., Shaffer D.R., Song X.T., Wu M.F., et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013, 21:1611-1620.
174. Kershaw M.H., Westwood J.A., Zhu Z., Witte L., Libutti S.K., Hwu P. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum Gene Ther 2000, 11:2445-2452.
175. Niederman T.M., Ghogawala Z., Carter B.S., Tompkins H.S., Russell M.M., Mulligan R.C. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A 2002, 99:7009-7014.
176. Chinnasamy D., Yu Z., Theoret M.R., Zhao Y., Shrimali R.K., Morgan R.A., et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. JClin Invest 2010, 120:3953-3968.
177. Chinnasamy D., Tran E., Yu Z., Morgan R.A., Restifo N.P., Rosenberg S.A. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res 2013, 73:3371-3380.
178. Wang W., Ma Y., Li J., Shi H.S., Wang L.Q., Guo F.C., et al. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther 2013, 20:970-978.
179. Ohno M., Natsume A., Ichiro I.K., Iwamizu H., Noritake K., Ito D., et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci 2010, 101:2518-2524.
180. Morgan R.A., Johnson L.A., Davis J.L., Zheng Z., Woolard K.D., Reap E.A., et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012, 23:1043-1053.
181. Zhou X., Li J., Wang Z., Chen Z., Qiu J., Zhang Y., et al. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia 2013, 15:544-553.
182. Shen C.J., Yang Y.X., Han E.Q., Cao N., Wang Y.F., Wang Y., et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. JHematol Oncol 2013, 6:33.
183. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009, 106:3360-3365.
184. Lanitis E., Poussin M., Hagemann I.S., Coukos G., Sandaltzopoulos R., Scholler N., et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 2012, 20:633-643.
185. Zhao Y., Moon E., Carpenito C., Paulos C.M., Liu X., Brennan A.L., et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010, 70:9053-9061.
186. Hekele A., Dall P., Moritz D., Wels W., Groner B., Herrlich P., et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int J Cancer 1996, 68:232-238.
187. Dall P., Herrmann I., Durst B., Stoff-Khalili M.A., Bauerschmitz G., Hanstein B., et al. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol Immunother 2005, 54:51-60.
188. Hombach A., Heuser C., Sircar R., Tillmann T., Diehl V., Kruis W., et al. Tcell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997, 113:1163-1170.
189. McGuinness R.P., Ge Y., Patel S.D., Kashmiri S.V., Lee H.S., Hand P.H., et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 1999, 10:165-173.
190. Mezzanzanica D., Canevari S., Mazzoni A., Figini M., Colnaghi M.I., Waks T., et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther 1998, 5:401-407.
191. Peinert S., Prince H.M., Guru P.M., Kershaw M.H., Smyth M.J., Trapani J.A., et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther 2010, 17:678-686.
192. Westwood J.A., Smyth M.J., Teng M.W., Moeller M., Trapani J.A., Scott A.M., et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005, 102:19051-19056.
193. Westwood J.A., Murray W.K., Trivett M., Haynes N.M., Solomon B., Mileshkin L., et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. JImmunother 2009, 32:292-301.
194. Wilkie S., Picco G., Foster J., Davies D.M., Julien S., Cooper L., et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. JImmunol 2008, 180:4901-4909.
195. Gattenlohner S., Marx A., Markfort B., Pscherer S., Landmeier S., Juergens H., et al. Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. Cancer Res 2006, 66:24-28.
196. Simon-Keller K., Barth S., Vincent A., Marx A. Targeting the fetal acetylcholine receptor in rhabdomyosarcoma. Expert Opin Ther Targets 2013, 17:127-138.
197. Gilham D.E., O'Neil A., Hughes C., Guest R.D., Kirillova N., Lehane M., et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. JImmunother 2002, 25:139-151.
198. Sheen A.J., Irlam J., Kirillova N., Guest R.D., Sherlock D.J., Hawkins R.E., et al. Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum 2003, 46:793-804.
199. Bridgeman J.S., Hawkins R.E., Bagley S., Blaylock M., Holland M., Gilham D.E. The optimal antigen response ofchimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation ofthe receptor into the endogenous TCR/CD3 complex. JImmunol 2010, 184:6938-6949.
200. Darcy P.K., Kershaw M.H., Trapani J.A., Smyth M.J. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody: redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 1998, 28:1663-1672.
201. Nolan K.F., Yun C.O., Akamatsu Y., Murphy J.C., Leung S.O., Beecham E.J., et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999, 5:3928-3941.
202. Hombach A., Wieczarkowiecz A., Marquardt T., Heuser C., Usai L., Pohl C., et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. JImmunol 2001, 167:6123-6131.
203. Haynes N.M., Trapani J.A., Teng M.W., Jackson J.T., Cerruti L., Jane S.M., et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. JImmunol 2002, 169:5780-5786.
204. Ma Q., DeMarte L., Wang Y., Stanners C.P., Junghans R.P. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther 2004, 11:297-306.
205. Emtage P.C., Lo A.S., Gomes E.M., Liu D.L., Gonzalo-Daganzo R.M., Junghans R.P. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res 2008, 14:8112-8122.
206. Shirasu N., Shibaguci H., Kuroki M., Yamada H., Kuroki M. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer Res 2010, 30:2731-2738.
207. Chmielewski M., Rappl G., Hombach A.A., Abken H. Tcells redirected by a CD3zeta chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term. Gene Ther 2013, 20:177-186.
208. Gyobu H., Tsuji T., Suzuki Y., Ohkuri T., Chamoto K., Kuroki M., et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 2004, 64:1490-1495.
209. Sasaki T., Ikeda H., Sato M., Ohkuri T., Abe H., Kuroki M., et al. Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. Cancer Sci 2006, 97:920-927.
210. Shibaguchi H., Luo N.X., Kuroki M., Zhao J., Huang J., Hachimine K., et al. Afully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer Res 2006, 26:4067-4072.
211. Chmielewski M., Hahn O., Rappl G., Nowak M., Schmidt-Wolf I.H., Hombach A.A., et al. Tcells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012, 143:1095-1107.
212. Ren-Heidenreich L., Hayman G.T., Trevor K.T. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. Hum Gene Ther 2000, 11:9-19.
213. Ren-Heidenreich L., Mordini R., Hayman G.T., Siebenlist R., LeFever A. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother 2002, 51:417-423.
214. Daly T., Royal R.E., Kershaw M.H., Treisman J., Wang G., Li W., et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 2000, 7:284-291.
215. Altenschmidt U., Kahl R., Moritz D., Schnierle B.S., Gerstmayer B., Wels W., et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996, 2:1001-1008.
216. Muniappan A., Banapour B., Lebkowski J., Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther 2000, 7:128-134.
217. Davies D.M., Foster J., van der Stegen S.J.C., Parente-Pereire A.C., Chiapero-Stanke L., Delinassios G.J., et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med 2012, 18:565-576.
218. Lo A.S., Ma Q., Liu D.L., Junghans R.P. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 2010, 16:2769-2780.
219. Yun C.O., Nolan K.F., Beecham E.J., Reisfeld R.A., Junghans R.P. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000, 2:449-459.
220. Morgenroth A., Cartellieri M., Schmitz M., Gunes S., Weigle B., Bachmann M., et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007, 67:1121-1131.
221. Katari U.L., Keirnan J.M., Worth A.C., Hodges S.E., Leen A.M., Fisher W.E., et al. Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 2011, 13:643-650.
222. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31:71-75.
223. Willemsen R.A., Weijtens M.E., Ronteltap C., Eshhar Z., Gratama J.W., Chames P., et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 2000, 7:1369-1377.
224. Willemsen R.A., Debets R., Hart E., Hoogenboom H.R., Bolhuis R.L., Chames P. Aphage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther 2001, 8:1601-1608.
225. Willemsen R.A., Ronteltap C., Chames P., Debets R., Bolhuis R.L. Tcell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. JImmunol 2005, 174:7853-7858.
226. Barber A., Zhang T., Sentman C.L. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. JImmunol 2008, 180:72-78.
227. Barber A., Rynda A., Sentman C.L. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. JImmunol 2009, 183:6939-6947.
228. Zhang T., Lemoi B.A., Sentman C.L. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005, 106:1544-1551.
229. Zhang T., Barber A., Sentman C.L. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res 2007, 67:11029-11036.
230. Zhang T., Sentman C.L. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. JImmunol 2013, 190:2455-2463.
231. Barber A., Zhang T., DeMars L.R., Conejo-Garcia J., Roby K.F., Sentman C.L. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007, 67:5003-5008.
232. Zhang T., Barber A., Sentman C.L. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 2006, 66:5927-5933.
233. Lehner M., Gotz G., Proff J., Schaft N., Dorrie J., Full F., et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 2012, 7:e31210.